The firm maintains a clean debt-free capital structure, yet total assets have contracted to $7.6 million as of 2026Q4, reflecting the ongoing erosion of equity due to a $67.1 million accumulated deficit.
| Total Current Assets | 7.58M | 9.61M | 9.39M | 865K | 2.05M |
| Cash & Short-Term Investments | 7M | 9.14M | 8.61M | 865K | 2.04M |
| Cash Only | 7M | 9.14M | 8.61M | 865K | 2.04M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 577K | 473K | 783K | 0 | 8.73K |
| Total Non-Current Assets | 19K | 197K | 16K | 0 | 0 |
| Property, Plant & Equipment | 19K | 21K | 16K | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 176K | 0 | 0 | 0 |
| Total Assets | 7.6M | 9.81M | 9.41M | 865K | 2.05M |
| Asset Turnover | - | - | - | - | - |
| Asset Growth % | -22.5% | 4.24% | 987.51% | -57.86% | - |
| Total Current Liabilities | 1.71M | 1.71M | 777K | 221K | 93.24K |
| Accounts Payable | 700K | 676K | 492K | 173K | 91.62K |
| Days Payables Outstanding | 21.29K | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 593K | 0 | 0 | 0 | 1.62K |
| Current Ratio | 4.45x | 5.63x | 12.09x | 3.91x | 22.02x |
| Quick Ratio | 4.45x | 5.63x | 12.09x | 3.91x | 22.02x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 1M | 0 | 0 |
| Long-Term Debt | 0 | 0 | 1M | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.71M | 1.71M | 1.78M | 221K | 93.24K |
| Total Debt | 0 | 0 | 1M | 0 | 0 |
| Net Debt | -7M | -9.14M | -7.61M | -865K | -2.04M |
| Debt / Equity | - | - | 0.13x | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | - | -63.83x | -194.27x | - | -62.33x |
| Total Equity | 5.89M | 8.1M | 7.63M | 644K | 1.96M |
| Equity Growth % | -27.21% | 6.17% | 1084.47% | -67.13% | - |
| Book Value per Share | 17.15 | 96.31 | 219.04 | 0.72 | 2.19 |
| Total Shareholders' Equity | 5.89M | 8.1M | 7.63M | 644K | 1.96M |
| Common Stock | 11K | 2K | 19K | 12K | 12K |
| Retained Earnings | -67.09M | -50.38M | -38.97M | -23.54M | -21.55M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
Clinical trial funding exhaustion
As reported in financial statements, Autonomix Medical's total assets have contracted from $12.0 million in 2025Q3 to $7.6 million by 2026Q4, reflecting a consistent depletion of resources as the company funds its ongoing clinical trial initiatives without the benefit of offsetting commercial revenue streams.
The downward trend in total assets suggests that the company is consuming its initial capital base to sustain R&D activities. Investors should monitor whether this trajectory necessitates a dilutive equity raise to maintain the current pace of clinical development.
Based on recent SEC filings, the company's cash position of $7.0 million as of 2026Q4, when evaluated against historical quarterly burn rates, indicates a narrowing liquidity buffer that may constrain the firm's ability to navigate unexpected regulatory delays or clinical trial site expansion costs.
While the current ratio of 4.45 appears superficially healthy, it is largely a function of low current liabilities rather than robust cash generation. This liquidity profile suggests that the company remains highly sensitive to capital market conditions and the timing of future funding rounds.
According to the provided balance sheet data, retained earnings have deteriorated to a deficit of $67.1 million by 2026Q4, highlighting the significant capital intensity required to advance the company's proprietary sensing technology through the necessary regulatory and clinical validation milestones.
The persistent growth of the accumulated deficit is a standard characteristic of pre-revenue medical device firms, yet it underscores the long-term reliance on external financing. The equity base remains thin, which may increase volatility for shareholders during periods of clinical data uncertainty.
As indicated by the company's financial statements, the asset base is almost entirely composed of cash, with net PPE of only $19,000 as of 2026Q4, suggesting that the firm's true value resides in intangible intellectual property rather than physical manufacturing or operational infrastructure.
The lack of significant tangible assets implies that the company's valuation is entirely dependent on the successful clinical validation of its sensing platform. This structure makes the balance sheet highly susceptible to impairment risk should the primary technology fail to meet its clinical endpoints.
Quick answers to the most common questions about buying AMIX stock.
As of 2026, Autonomix Medical, Inc. (AMIX) had total assets of $7.6M including $7.6M in current assets.
Autonomix Medical, Inc. (AMIX) carries total debt of $0.0M, offset by $7.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Autonomix Medical, Inc. (AMIX) has total shareholders' equity (book value) of $5.9M ($17.15 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Autonomix Medical, Inc. (AMIX) reported a current ratio of 4.45x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.